We're all set for a new experience. To visit the old Ventura website, click here.
Ventura Wealth Clients
2 min Read
Share

Clinitech Laboratory, a provider of diagnostic and healthcare tests, is set to launch its initial public offering (IPO) on July 25, 2024. This blog dives into the key details of the IPO, helping you make informed investment decisions.

About Clinitech Laboratory 

Founded in 1990, Clinitech Laboratory has carved a niche in the diagnostic service sector around Thane and Navi Mumbai. They boast a network of eight diagnostic centres equipped with modern technology and NABL accreditation, a testament to their commitment to quality testing. The company offers a wide range of tests across various categories, catering to diverse healthcare needs.

Clinitech Laboratory IPO fundamentals

  • Issue Type: Fixed Price Issue
  • Issue Size: ₹ 5.78 Crore
  • Fresh Issue: Entirely fresh issue of 6,02,400 shares
  • Offer Period: July 25, 2024 - July 29, 2024
  • Expected Allotment: July 30, 2024
  • Listing Venue: BSE SME (tentative listing date: August 1, 2024)
  • Issue Price: ₹ 96 per Share
  • Minimum Lot Size: 1200 Shares (Retail Investors: ₹ 1,15,200 minimum investment)
  • HNI Minimum Lot: 2 Lots (2,400 Shares - ₹ 2,30,400 minimum investment)

Clinitech Laboratory financials

  • Revenue: Increase of 1.19%
  • Profit After Tax (PAT): Decrease of 39.46%

Key considerations of the Clinitech Laboratory IPO

  • Growth: While Clinitech Lab demonstrates consistent revenue, the recent decline in PAT is a cause for concern. Potential investors should carefully analyse the reasons behind this drop before subscribing to the Clinitech Laboratory IPO.
  • Market & Competition: The diagnostic industry is witnessing significant growth. Understanding Clinitech's competitive edge and strategy for future expansion is crucial.
  • Expansion Plans: The company plans to utilise the IPO investment proceeds for expanding diagnostic centres. Investors should assess the feasibility and potential impact of this expansion.

Clinitech Laboratory IPO listing

Clinitech Laboratory will be listed on the BSE SME platform, catering to smaller companies. This platform typically has lower liquidity compared to the main board. Investors should be comfortable with a less active trading environment.

Conclusion

Clinitech Laboratory IPO presents an opportunity to invest in a growing healthcare service provider. However, a thorough analysis of the company's financials, future prospects, and the overall market landscape is essential before making an IPO investment decision. Consulting a financial advisor can be beneficial for personalised guidance.

Disclaimer: This blog is for informational purposes only and should not be considered investment advice. It's advisable to consult a financial advisor before investing in any IPO.